Some days ago we commented on a media release issued by Myriad Genetics which stated that their new PROLARIS™ test “identifies patients at low risk of disease recurrence with 95% certainty.” We have now been able to see the actual data presented by Swanson et al. at the Genitourinary Cancers Symposium in San Francisco. It […]Image may be NSFW.
Clik here to view.
Clik here to view.
